ArticleRespirology case reports2025
Myeloperoxidase-Antibody Positivity and Progression to Microscopic Polyangiitis in Interstitial Lung Disease: A Case Series.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevalence and clinical outcomes of fibrotic interstitial lung disease in ANCA associated vasculitis: a single-centre, retrospective, cohort study.Respiratory research · 2026Article
- Myeloperoxidase-Antibody Positivity and Progression to Microscopic Polyangiitis in Interstitial Lung Disease: A Case Series.Respirology case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microscopic polyangiitis (MPA) is associated with myeloperoxidase-antibody positivity and pulmonary complications. However, these antibodies may be found incidentally in some people with interstitial lung disease (ILD). As a result, management of people with ILD and myeloperoxidase-antibody positivity remains unclear. Our case series describes the natural history of this group of patients over a mean follow-up period of 4 years. Using data from a public sector pathology provider in Western Australia, we identified 17 people with a positive myeloperoxidase-antibody titre and who attended our tertiary Respiratory outpatient clinic. Eventual or concurrent diagnosis of MPA was more common in those with radiological usual interstitial pneumonia pattern, higher baseline and peak myeloperoxidase-antibody titres, lower gas transfer capacity and lower distances achieved on 6-min walk testing. These features may be used by clinicians during multidisciplinary team discussion to identify those at high-risk of developing MPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.